Associations of HDL phospholipids and paraoxonase activity with coronary heart disease in postmenopausal women

Acta Physiologica Scandinavica

Volumn 176, Issue 2, 2002, Pages 123-130

  Horter, M J ^a   Sondermann, S ^a   Reinecke, H ^a   Bogdanski, J ^a   Woltering, A ^a   Kerber, S ^a   Breithardt, G ^a   Assmann, G ^a   Von Eckardstein, A ^a,b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Atherosclerosis; Coronary risk factors; HDL; Insulin resistance; Oxidation; Phospholipids; Reverse cholesterol transport

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; C PEPTIDE; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE; SPHINGOMYELIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; INFLAMMATION; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; APOLIPOPROTEINS B; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; CORONARY DISEASE; ESTERASES; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; LIPOPROTEINS, HDL; MIDDLE AGED; PHOSPHOLIPIDS; POSTMENOPAUSE; RISK FACTORS; TRIGLYCERIDES;

EID: 0036403237     PISSN: 00016772     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-201X.2002.01021.x     Document Type: Article

References (35)

1. Aviram, M., Billecke, S., Sorenson, S. et al. 1998. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities. Selective action on human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 18, 1617-1624.
2. Baker, P.W., Rye, K.A., Gamble, J.R., Vadas, M.A. & Barter, P.J. 2000. Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression. J Lipid Res 41, 1261-1267.
3. Bolibar, I., von Eckardstein, A., Assmann, G. & Thompson, S. on behalf of the ECAT Angina Pectoris Study Group 2000. Short-term prognostic value of lipid measurements for coronary events in patients with angina pectoris. Thromb Haemost 84, 955-960.
4. De la Llera Moya, M., Atger, V., Paul, J.L. et al. 1994. A cell culture system for screening human serum for ability to promote cholesterol efflux. Relations between serum components and efflux, esterification, and transfer. Arterioscler Thromb 14, 1056-1065.
5. Durrington, P.N., Mackness, B. & Mackness, M.I. 2001. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21, 473.
6. von Eckardstein, A., Nofer, J.-R. & Assmann, G. 2001. High density lipoproteins and arteriosclerosis. Arterioscler Thromb Vasc Biol 21, 13-21.
7. Eckerson, H.W., Wyte, C. & La Du, B.N. 1983. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 35, 1126-1138.
8. Enbergs, A., Dorszewski, A., Luft, M. et al. 1998. Failure to confirm ferritin and coeruloplasmin as risk factors for the extent of coronary arteriosclerosis. Coronary Artery Dis 9, 119-124.
9. Erren, M., Reinecke, H., Junker, R. et al. 1999. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 19, 2355-2363.
10. Fournier, N., Paul, J.-L., Atger, V. et al. 1997. HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum. Arterioscler Thromb Vasc Biol 17, 2685-2691.
11. Fröhlich, M., Imhof, A., Berg, G. et al. 2000. Association between C-reactive protein and features of the metabolic syndrome. Dia Care 23, 1835-1839.
12. Furlong, C.E., Richter, R.J., Seidel, S.L., Costa, L.C. & Motulsky, A.G. 1989. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlopyrifos and parathion by serum paraoxonase/arylesterase. Anal Biochem 180, 242-247.
13. Garin, M.C.B., Abbot, C., Messmer, S. et al. 1994. Quantification of human serum paraoxonase by enzyme linked immunoassay: population differences in protein concentrations. Biochem J 304, 549-554.
14. Ginsberg, H.N. & Huang, L.S. 2000. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk 7, 325-331.
15. Humbert, R., Adler, D.A., Disteche, C.M., Hassett, C., Omiecinski, C.J. & Furlong, C.E. 1993. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3, 598-608.
16. Jiang, T.-S., Schissel, S.L., Tabas, I., Pownall, H.J., Tall, A.R. & Jiang, X.-C. 1998. Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. Clin Invest 101, 905-912.
17. Jiang, X.-C., Paultre, F., Pearson, T.A. et al. 2000. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 20, 2614.
18. Laplaud, P.M., Dantoine, T. & Chapman, M.J. 1998. Paraoxonase as a risk marker for cardiovascular disease: facts and hypotheses. Clin Chem Laboratory Med 36, 431-441.
19. Mackness, M.I., Mackness, B., Durrington, P.N. et al. 1998. Paraoxonase and coronary heart disease. Curr Opin Lindol 9, 319-324.
20. Maron, D.J. 2000. The epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease. Am J Cardiol 21, 11L-14L.
21. Navab, M., Hama, S.Y., Hough, G.P. et al. 1998. High density assoziated enzymes: their role in vascular biology. Curr Opin Lindol 9, 449-456.
22. Nie, N.H. 1983. SPSSX User's Guide. McGraw-Hill, New York.
23. Nofer, J.R., Fobker, M., Höbbel, G. et al. 2000. Activation of phosphatidylinositol-specific phospholipase C (PI-PLC) by HDL-associated lysosphingolipids. Involvement but not in cholesterol efflux. Biochemistry 39, 15199-15207.
24. Nofer, J.R., Kehrel, B., Fobker, M., Levkau, B., Assmann, G. & von Eckardstein, A. 2002. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 161, 1-16.
25. Nofer, J.R., Levkau, B., Wolinska, I. et al. 2001. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem 276, 34480-34485.
26. Rothblat, G.H., de la Llera Moya, M., Atger, V., Kellner-Weibel, G., Williams, D.L. & Phillips, M.C. 1999. Cell cholesterol efflux: integration of old and new observtions provides new insights. J Lipid Res 40, 781-796.
27. Rye, K.-A., Hime, N.J. & Barter, P.J. 1996. The influence of sphingomyelin on the structure and function of reconstituted high density lipoproteins. J Biol Chem 271, 4243-4250.
28. Schriewer, H., Jabs, H.-U. & Assmann, G. 1982. Zur enzymatischen Bestimmung des HDL Sphingomyelins. J Clin Chem Clin Biochem 20, 310-312.
29. Schriewer, H., Jung, G., Emke, F. & Assmann, G. 1983. An economical assay for HDL phosphatidylcholine. J Clin Chem Clin Biochem 21, 611-614.
30. Subbaiah, P.V. & Liu, M. 1993. Role of sphingomyelin in the regulation of cholesterol esterification in the plasma lipoproteins. Inhibition of lecithin-cholesterol acyltansferase reaction. J Biol Chem 268, 20156-20163.
31. Subbaiah, P.V., Subramanian, V.S. & Wang, K. 1999. Novel physiological function of sphingomyelin in plasma. J Biol Chem 274, 36409-36414.
32. Tataru, M.C., Heinrich, J., Junker, R. et al. 2000. C-reactives protein and the severity of atherosklerosis in myocardial infarction patients with stable angina pectoris. Eur Heart J 21, 1000-1008.
33. Van Lenten, B.J., Hama, S.Y., de Beer, F.C. et al. 1995. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. J Clin Invest 96, 2758-2767.
34. Weintraub, W.S. & Harrison, D.G. 2000. C-reactive protein, inflammation and atherosclerosis: do we really understand it yet? Eur Heart J 21, 958-960.
35. Yancey, P.G., de la Llera-Moya, M., Swarnakar, S. et al. 2000. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J Biol Chem 283, 36596-36604.